Ligand Pharmaceuticals
LGND
132 hedge funds and large institutions have $713M invested in Ligand Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 33 increasing their positions, 49 reducing their positions, and 17 closing their positions.
94% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 17
14% more funds holding
Funds holding: 116 → 132 (+16)
11% more capital invested
Capital invested by funds: $640M → $713M (+$72.7M)
33% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 49
41% less call options, than puts
Call options by funds: $3.07M | Put options by funds: $5.23M
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIM
RS Investment Management
San Francisco,
California
|
+$26.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$20M |
| 3 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
+$15.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$11.4M |
| 5 |
William Blair & Company
Chicago,
Illinois
|
+$9.74M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$45.5M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$21.1M |
| 3 |
ACMM
Arbor Capital Management (Minnesota)
Minneapolis,
Minnesota
|
-$17.9M |
| 4 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$16.1M |
| 5 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
-$11.9M |
LGND Hedge Fund Activity: Q3 2013 in Review
132 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q3 2013, worth a combined $713M — up 11% from $640M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new LGND positions and 17 closed out — a net gain of 16 holders — while 33 added to existing stakes and 49 trimmed.
The largest buyer was RS Investment Management, opening a new position worth an estimated $26.7M. The largest seller was UBS AM, cutting an estimated $45.5M.
- 132 institutional investors held Ligand Pharmaceuticals (LGND) as of Q3 2013, up from 116 in Q2 2013.
- Funds reported $713M of Ligand Pharmaceuticals stock for Q3 2013, up 11% quarter-over-quarter.
- 33 funds opened new Ligand Pharmaceuticals positions in Q3 2013 and 17 closed out, a net change of +16 holders.
- The largest Ligand Pharmaceuticals buyer in Q3 2013 was RS Investment Management, an estimated $26.7M added.
- The largest Ligand Pharmaceuticals seller in Q3 2013 was UBS AM, an estimated $45.5M sold.
Based on aggregated 13F filings for Q3 2013.